biologics

(redirected from Biologic therapy)
Also found in: Dictionary.

biologics

biological products such as VACCINES and therapeutic sera (see SERUM), used to induce IMMUNITY to infectious diseases or harmful substances of biological origin.
References in periodicals archive ?
It remains uncertain how to manage RA patients with a negative initial screening for TST or IGRA on chronic biologic therapy.
To our knowledge, the patient has not had any more pulmonary symptoms upon reinitiation of biologic therapy
There are several potential mechanisms by which MTX might improve response to biologic therapy in RA, from abrogation of antibody development to the biologic, to inhibition of clearance of the biologic, to synergism of effects on the disease process itself.
There is even some evidence that patients can return with success to a biologic therapy that they had previously failed.
First use of an advanced biologic therapy occurred at a mean of 28 days in 2,517 patients who presented with a diabetic neuropathic foot ulcer between Jan.
have debuted the first trial comparing biologic therapy with conventional therapy in patients with Crohn's disease.
Food and Drug Administration approved the first biologic therapy for psoriasis, Amevive (alefacept), an injected medication.
These approaches include biologic therapy using interleukin (IL)-2, IL-12, interferon-alpha, monoclonal antibodies directed against B cell targets, cytotoxic T lymphocytes directed against viral targets, immune-based therapy, stem cell reconstitution, angiogenesis inhibitors, therapeutic vaccines, and traditional cytotoxic chemotherapy regimens (often in combination with a biologic or immunologic approach).
The first such biologic therapy for psoriasis to be approved.
According to TreatmentTrends: Rheumatoid Arthritis (EU) 2012, most surveyed EU5 physicians indicate their use of biologic agents to treat their RA patients has increased, and they are also initiating biologic therapy earlier and being more aggressive with these agents.
Factors influencing individual patient response to biologic therapy include systemic inflammation, other drug therapies, pharmacogenetic factors, disease phenotype, body mass, immunogenicity, immunomodulators, and the presence of anti-drug antibodies.
Nucala (mepolizumab) is the first biologic therapy that targets interleukin-5 (IL-5) - the main promotor of eosinophil growth, activation and survival - in severe asthma.